IFF Launches Dog-Specific Probiotic with Canine-Derived L. reuteri Strain
IFF is launching PureStrong™, a probiotic for dogs built around one Limosilactobacillus reuteri strain sourced from healthy canines to optimize survival and competition in their guts. In a controlled diet-change study, dogs receiving PureStrong™ had firmer stools, improved hydration and better diet tolerance, tapping into the $3.2 billion U.S. pet supplement market.
1. Product Overview
PureStrong™ is a single-strain probiotic for canine digestive health, featuring Limosilactobacillus reuteri sourced directly from healthy dog microbiomes. Unlike generic human or livestock blends, this targeted strain is optimized to survive, attach and compete in the canine gut and can be formulated into powders, capsules, tablets or sticks.
2. Market Opportunity
The U.S. pet supplement market is valued at $3.2 billion, driven by rising pet wellness spending and nearly half of dog owners using or considering probiotics. IFF’s HOWARU® Pet portfolio leverages decades of microbiome science to help pet health brands differentiate with precision-wellness offerings.
3. Clinical Study Results
In a controlled study on dogs undergoing abrupt diet changes, PureStrong™ recipients exhibited improved markers of digestive health including firmer stools, enhanced hydration and increased diet tolerance without signs of constipation. These results demonstrate the strain’s real-world support for canine gut health.